Time filter

Source Type

Hamburg, Germany

Evotec AG is a drug discovery alliance and development partnership company focused on progressing product approaches with pharmaceutical and biotechnology companies.The company's headquarters are located in Hamburg, Germany. It operates worldwide providing integrated drug discovery solutions, covering all activities from target-to-clinic.Evotec employs over 500 scientists and works in key therapeutic areas including CNS/neurology , metabolic diseases such as diabetes, as well as oncology, inflammation and infectious diseases. The company has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, the CHDI Foundation, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development.In fiscal year 2013, Evotec generated revenues of €85.94 m. At the end of September 2014, Evotec had 718 employees.Since 28 October 2009 the company is listed in the TecDAX index. Wikipedia.

Small molecule inhibitors of protein kinases are key tools for signal transduction research and represent a major class of targeted drugs. Recent developments in quantitative proteomics enable an unbiased view on kinase inhibitor selectivity and modes of action in the biological context. While chemical proteomics techniques utilizing quantitative mass spectrometry interrogate both target specificity and affinity in cellular extracts, proteome-wide phosphorylation analyses upon kinase inhibitor treatment identify signal transduction pathway and network regulation in an unbiased manner. Thus, critical information is provided to promote new insights into mechanisms of kinase signaling and their relevance for kinase inhibitor drug discovery. © 2014 American Chemical Society. Source

Duncton M.A.J.,Evotec | Duncton M.A.J.,Rigel Inc

The addition of a radical to a heteroaromatic base is commonly referred to as a Minsici reaction. Such reactions constitute a broad-set of selective CH-functionalization processes. This review describes some of the major applications of Minisci reactions and related processes to medicinal or biological chemistry, and highlights some potential developments within this area. © 2011 The Royal Society of Chemistry. Source

Evotec | Date: 2015-04-08

The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.

The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.

The present invention discloses a dysregulation of the KCNN3 gene and the protein products thereof in Alzheimers disease patients and individuals being at risk of developing Alzheimers disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimers disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimers disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimers disease and related neurodegenerative disorders using the KCNN3 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.

Discover hidden collaborations